Diabetic retinopathy is the most frequently occurring complication of diabetes mellitus and
remains a leading cause of vision loss globally. Its aetiology and pathology have been …

There are two major types of ocular neovascularization that affect the retina, retinal
neovascularization (NV) and subretinal or choroidal NV. Retinal NV occurs in a group of …

Purpose A head-to-head comparison was performed between vascular endothelial growth
factor blockade and laser for treatment of diabetic macular edema (DME). Design Two …

Purpose To report 36-month outcomes of RIDE (NCT00473382) and RISE (NCT00473330),
trials of ranibizumab in diabetic macular edema (DME). Design Phase III, randomized …

PURPOSE: To evaluate the efficacy and safety of intravitreal ranibizumab in diabetic
macular edema (DME) patients. DESIGN: Two parallel, methodologically identical, phase III …

Diabetes mellitus (DM) is a important health problem that induces ernestful complications
and it causes significant morbidity owing to specific microvascular complications such as …

OBJECTIVE: Evaluate intravitreal 0.5 mg ranibizumab or 4 mg triamcinolone combined with
focal/grid laser compared with focal/grid laser alone for treatment of diabetic macular edema …

OBJECTIVE The expression of vascular endothelial growth factor (VEGF) is elevated in
diabetic macular edema (DME). Ranibizumab binds to and inhibits multiple VEGF variants …

Background Diabetic macular oedema (DMO) is a common complication of diabetic
retinopathy. Although grid or focal laser photocoagulation has been shown to reduce the risk …

Clinical efficacy of intravitreal anti-VEGF drugs has been widely demonstrated in several
angiogenesis-driven eye diseases including diabetic macular edema and the neovascular …